We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Antibody Conjugates for in-Vitro Imaging Applications Visualize and Quantify Proteins

By Biotechdaily staff writers
Posted on 31 May 2007
A new line of antibody conjugates for in vitro imaging applications is now available for biomedical researchers.

The Kodak X-Sight antibody conjugates for in vitro applications augment the line of conjugates for in vivo use that had been previously released by Carestream Health, Inc. More...
(New Haven, CT, USA).

The new antibody conjugates are designed for Western blotting applications, which use gel electrophoresis to separate proteins from a sample of cell or tissue based on molecular weight and size. After protein separation, a primary antibody targets the specific protein of interest. The Kodak X-Sight antibody conjugates then attach to the primary antibody and light up when excited by the appropriate wavelength of fluorescent light, thus allowing researchers to visualize and quantify the protein under investigation.

To minimize cross reactivity, the secondary antibodies have been affinity purified and are highly cross-absorbed. This treatment purportedly results in superior brightness, higher sensitivity, and excellent signal to noise results when compared to other commercially available conjugates. Conjugates are available conjugated to a variety of secondary antibodies in four distinct excitation and emission wavelengths ranging from just above ultraviolet (UV) to near infrared (IR), making them suitable for multiplex detection of proteins. While the antibody conjugates have been optimized for Kodak Image Station Systems instruments, they are also compatible with other commercially available digital imaging systems.

"The continuous introduction of novel Kodak X-Sight imaging agents is a sign of our commitment towards offering our customers a complete solution for their imaging needs. We are very excited about this proprietary product line with its demonstrated significant improvements in protein detection and other in-vitro applications over existing available products,” said Dr. Shahram Hejazi, president of Carestream Health's molecular imaging systems division.


Related Links:
Carestream Health

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Portable POCT Blood Gas Analyzer
BD100
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.